CCM
ACOR

Chilton Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Chilton Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,189
Closed -$311K – 219
2021
Q1 		$311K Buy
+3,189
New +$392K 0.02% 165

Other funds holding ACOR

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Chilton Capital Management's ACOR Position: Q2 2021 in Review

Chilton Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2021, closing a stake of 3,189 shares — an estimated $311K sold.

Chilton Capital Management first reported a position in ACOR in Q1 2021 and held it in 1 quarter. The position peaked at $311K in Q1 2021. 34 funds tracked by Wall St. Rank hold ACOR as of Q2 2021.

  • Chilton Capital Management reported no remaining Acorda Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Chilton Capital Management sold 3,189 Acorda Therapeutics shares in Q2 2021, an estimated $311K.
  • Chilton Capital Management first reported a position in Acorda Therapeutics in Q1 2021 and held it in 1 quarter.
  • Chilton Capital Management's Acorda Therapeutics position peaked at $311K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2021.

Based on Chilton Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.